Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients

PURPOSE: Resistance to cetuximab, a monoclonal antibody against the epithelial growth factor receptor (EGFR), in colorectal cancer (CRC) may result from compensatory signaling through ErbB receptors, ErbB2/neu/HER2 (HER2) and ErbB3/HER3 (HER3). Pertuzumab is a monoclonal antibody that blocks HER2 he...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Rubinson, Douglas A., Hochster, Howard S., Ryan, David P., Wolpin, Brian M., McCleary, Nadine Jackson, Abrams, Thomas A., Chan, Jennifer A., Iqbal, Syma, Lenz, Heinz J., Lim, Dean, Rose, Jeffrey, Bekaii-Saab, Tanios, Chen, Helen X., Fuchs, Charles S., Ng, Kimmie
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3775976/
https://ncbi.nlm.nih.gov/pubmed/23568716
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-9956-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados